GLP-1 Receptor Agonist Market Trends

GLP-1 Receptor Agonist Market Trends

The prevalence of chronic diseases like diabetes, cardiovascular diseases, obesity, and many others has been rapidly increasing over the past few decades. The prevalence of diabetes is increasing at an alarming rate all over the globe. For instance, according to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, in 2021, approximately 537 million adults were living with diabetes, and it is estimated that by 2030, the number of diabetic patients will reach 643 million and by 2045, 783 million worldwide. According to the IDF, in 2021, diabetes is expected to cause 6.7 million deaths. Among type 1 and type 2 diabetes, the most common is type 2, which usually occurs in adults.
 

The global obesity crisis is affecting the heart, kidneys, liver, and mental health. It leads to a wide range of diseases like type 2 diabetes, cardiovascular diseases, hypertension, stroke, and cancer. According to the World Health Organization, in 2022, more than 1 billion people were obese, of whom 650 million were adults, 340 million were adolescents, and 39 million were children. The prevalence of diabetes and obesity is still increasing, and the need to treat such chronic diseases has become crucial. Glucagon-like peptide-1 receptor agonists (GLP-1) are a class of drugs mostly used for treating diabetes and obesity. The high prevalence of diabetes and obesity is expected to amplify the growth of the GLP-1 receptor agonist market globally.
 

Due to the rising prevalence and demand for novel therapeutics for treating diseases like diabetes, obesity, cardiovascular disorders and many others are boosting the growth of global market. The pharmaceutical companies are increasing the research and development activities for developing novel GLP-1 receptor agonist drugs in order to overcome the health and mental issues caused by obesity and diabetes.